Some congress participants subscribed to the view that anyone with a heterozygous COL4A3 or COL4A4 mutation should be diagnosed with Alport syndrome, to ensure that the significance of their diagnosis is appreciated and to ensure aggressive management and long-term monitoring [21]. This evidence concerns the gene COL4A4 and Alport syndrome.